DOYLESTOWN, Pa., Feb. 11 Gold Partners, a premier clinical and regulatory retained search firm, announced the appointment of Larry Bell, M.D., as President, Regulatory, Quality, Safety and Risk Management Services. This will allow Gold Partners to harness Dr. Bell's extensive drug development knowledge, as well as his practical and personal experiences in project life cycle management, providing an unparalleled strategic force in developing pharmaceutical leadership.
"We believe that the synergies created by Dr. Bell's solid knowledge of clinical and regulatory medical team structures and his broad range of industry contacts, combined with Gold Partners' 20-plus years of successful clinical and regulatory search affords a unique offering in the marketplace that will meet both the current and future needs of our corporate clients," stated Gold Partners founder Mark Gold.
"Pharmaceutical companies need to be concerned with the life cycle management of both products and personnel. We have the experience, insight, proven track record and now the consultative services of Dr. Bell," according to Gold. "By adding Dr. Bell to our team, we can provide a broader and deeper array of services to move our clients' businesses forward and also expand our scope towards the growing smaller to mid-sized biotech and pharmaceutical companies," added Gold. "Larry has been a leader in drug approval efforts at several major companies, and he knows how to develop and inspire a team," reflects Bryan Shea, chief operating officer of Gold Partners. "Thorough assessment of client goals combined with an understanding of the broader business needs assures me that we can provide the best possible talent at the optimal time in a product's life cycle, and that a candidate's experience is critical to affecting optimal development," remarked Dr. Bell.
About Dr. Bell
Prior to his position at Gold Partners, Dr. Bell has held positions of increasing areas of responsibility. Most recently, he was Global Head of Regulatory Affairs, Pharmacovigilance and Risk Management at GE HealthCare (GEHC), Medical Diagnostics. Previously he held executive positions at Amgen, Inc., Aventis Pharmaceuticals, Merck and Bristol-Myers-Squibb Pharmaceutical Research Institute (BMSPRI). For more information about Gold Partners, please go to http://www.searchgold.com.
SOURCE Gold Partners